This creates a different but still powerful combination
The self-pay segment includes patients willing to bear substantial out-of-pocket costs averaging USD 1000 per month to access treatment not covered by their insurance plans
Two appetite-regulating hormones produced in the digestive tract, ghrelin, an appetite stimulant and pancreatic peptide Y (PYY), a appetite suppressant have been linked to short-term feed behaviors, whereas leptin and to a lesser extent, insulin, are key to chronic weight maintenance over months and years (1)
Plan around MOTS-c's 7-day window MOTS-c is reconstituted-stable for about 7 days at 2-8 C before potency starts to drop
Key Points Summary Asias GLP1 uptake has lagged the West but is primed for rapid acceleration as obesity rates rise and government urgency grows China and India are driving demand shifts as diets westernise and metabolic disease climbs Cost barriers are falling: local firms in China and India are developing cheaper semaglutide generics, forcing price cuts Mintel forecasts explosive growth, with China potentially becoming the worlds No1 GLP1 market by 2030 Safety fears persist in China (side effects, rebound, semaglutide face) and in India (strict rules on drug promotion) GLP-1 agonist drugs have revolutionised weight loss in the United States and parts of Europe, providing in most cases a highly effective way to manage the ballooning issue of obesity in these markets
Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial
